Conbercept for patients with age-related macular degeneration: a systematic review

Abstract

BackgroundConbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD). This systematic review aims to assess the efficacy and safety of conbercept in the treatment of wet AMD.MethodsPubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP database, and Wanfang database were searched from their earliest records to June 2017. We included randomized controlled trials (RCTs) evaluating the efficacy and safety of conbercept in wet AMD patients. Outcomes included the mean changes from baseline in best-corrected visual acuity (BCVA) score (primary outcome), central retinal thickness (CRT), plasma level of vascular endothelial growth factor (VEGF) over time, and the incidence of adverse events (AEs).ResultsEighteen RCTs (1285 participants) were included in this systematic review. Conbercept might improve BCVA compared to triamcinolone acetonide [MD = 0.11, 95% CI (0.08, 0.15)], and reduce CRT compared to the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide). The incidence of AEs in patients receiving conbercept was significantly lower than those receiving triamcinolone acetonide [RR = 0.25, 95% CI (0.09–0.72)], but was similar to the other therapies. Conbercept seemed to be more effective than ranibizumab in lowering the plasma level of VEGF [MD = − 15.86, 95% CI (− 23.17, − 8.55)].ConclusionsCurrent evidence shows that conbercept is a promising option for the treatment of wet AMD. Nevertheless, further studies are required to compare the efficacy, long-term safety and cost-effectiveness between conbercept and other anti-VEGF agents in different populations.Electronic supplementary materialThe online version of this article (10.1186/s12886-018-0807-1) contains supplementary material, which is available to authorized users.

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis

“…Previous meta-analyses in nAMD had stated that conbercept was more efficacious and safer compared with ranibizumab when neglecting treatment frequency. 4,47,48 Whereas conbercept quarterly was significantly inferior in terms of efficacy to all types of ranibizumab regimen except ranibizumab quarterly regimen in our NMA. The evidence mentioned previously can also be found in mean BCVA change.…”

Age-Related Macular Degeneration Preferred Practice Pattern®

“…Aflibercept, ranibizumab, and pegaptanib-injection product labeling and other literature discuss techniques of intravitreal injection. 181,207,[239][240][241] Recently, conbercept has shown promising results in the management of wet AMD, 242 although it has yet to receive FDA approval for its use. Similarly, abicipar has completed phase II clinical trials and has shown an extended duration of effect with a good safety profile; however, it has not received FDA approval.…”

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

“…17 Previous studies have shown that conbercept can improve a variety of clinical symptoms, such as best corrected visual acuity (BCVA), central foveal thickness (CFT), and choroidal neovascularization area. 18 Conbercept has been used in the treatment of diabetic macular edema, 17 wet age-related macular degeneration, 19 chronic central serous chorioretinopathy, 20 and proliferative diabetic retinopathy. 14 However, conbercept has not been reported as a common treatment for NPDR.…”